Drug Trial Radar · NCT00047632
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 1, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
847
Actual
Start
Oct 2001
Primary completion
Not stated
Study completion Feb 2006
Sponsor
- Lead sponsor
- InterMuneIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of this study are to determine: 1) if treatment with interferon gamma-1b plus standard chemotherapy (carboplatin and paclitaxel) can increase the overall survival of patients with advanced ovarian or primary peritoneal carcinoma compared with chemotherapy alone; 2) how effective interferon gamma-1b plus standard chemotherapy is in preventing the progression or return of cancer; 3) the effects on quality of life; and 4) the safety of interferon gamma-1b combined with standard chemotherapy compared to chemotherapy alone.
Conditions
- Ovarian Carcinoma
- Peritoneal Carcinoma
Interventions
Interferon gamma-1bDrug
100 mcg, SQ, 3x per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival time assessed at end of studyTime frame: 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
InterMune, Inc.
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.